ScreenerHero

TTRX Turn Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · turntherapeutics.com
12.10USD+3.95%Mkt Cap: 367.45M $P/E: —

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic thro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap367.45M USD
Enterprise Value342.57M USD
Revenue (TTM)—
Gross Profit-1.61M USD
Net Income (TTM)-3.19M USD
Revenue/Share—
Last Price12.10 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-77.60
PEG—
EV/EBITDA-40.27
EV/Revenue—
P/S—
P/B506.09
EPS (TTM)-0.29
EPS (Forward)-0.15
52W Range
2.57040% of range26.50
52W High26.50 USD
52W Low2.570 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.15%
ROA-26.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.56M USD
CapEx (TTM)152.99K USD
FCF Margin—
FCF Yield1.13%
Net Debt-4.17M USD
Net Debt/EBITDA0.49
Balance Sheet
Debt/Equity0.02
Current Ratio1.19
Quick Ratio1.17
Book Value/Sh0.02 USD
Cash/Share0.34 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.00 USD
Upside (mean)+106.6%
Target Range24.00 USD – 26.00 USD
24.00+106.6% to mean26.00
# Analysts2
Ownership
Shares Out.30.37M
Float10.83M
Insiders53.88%
Institutions3.88%
Short Interest
Short Ratio1.8d
Short % Out.0.51%
Shares Short154.37K
Short (prev mo.)114.83K
Technical
SMA 5011.11 (+8.9%)
SMA 2006.331 (+91.1%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)150.91K
Avg Vol (10d)117.35K
Technical Indicators
RSI (14)47.3
MACD0.3211
MACD Signal0.6872
MACD Hist.-0.3661
BB Upper15.41 USD
BB Middle13.45 USD
BB Lower11.48 USD
BB Width29.20%
ATR (14)1.292 USD
Vol Ratio (20d)1.00x